|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DDX60 |
Gene summary for DDX60 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DDX60 | Gene ID | 55601 |
| Gene name | DExD/H-box helicase 60 | |
| Gene Alias | DDX60 | |
| Cytomap | 4q32.3 | |
| Gene Type | protein-coding | GO ID | GO:0002221 | UniProtAcc | Q6B0F7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55601 | DDX60 | LZE5T | Human | Esophagus | ESCC | 1.95e-02 | 2.61e-01 | 0.0514 |
| 55601 | DDX60 | LZE8T | Human | Esophagus | ESCC | 2.74e-04 | 1.37e-01 | 0.067 |
| 55601 | DDX60 | LZE20T | Human | Esophagus | ESCC | 9.67e-07 | 1.67e-01 | 0.0662 |
| 55601 | DDX60 | LZE24T | Human | Esophagus | ESCC | 1.73e-15 | 5.58e-01 | 0.0596 |
| 55601 | DDX60 | P1T-E | Human | Esophagus | ESCC | 3.60e-06 | 2.58e-01 | 0.0875 |
| 55601 | DDX60 | P2T-E | Human | Esophagus | ESCC | 9.23e-48 | 8.57e-01 | 0.1177 |
| 55601 | DDX60 | P4T-E | Human | Esophagus | ESCC | 6.03e-05 | 8.93e-02 | 0.1323 |
| 55601 | DDX60 | P5T-E | Human | Esophagus | ESCC | 6.03e-08 | 1.97e-01 | 0.1327 |
| 55601 | DDX60 | P8T-E | Human | Esophagus | ESCC | 1.40e-12 | 3.02e-01 | 0.0889 |
| 55601 | DDX60 | P9T-E | Human | Esophagus | ESCC | 5.04e-15 | 1.50e-01 | 0.1131 |
| 55601 | DDX60 | P11T-E | Human | Esophagus | ESCC | 6.89e-10 | 4.83e-01 | 0.1426 |
| 55601 | DDX60 | P12T-E | Human | Esophagus | ESCC | 6.61e-09 | 2.34e-01 | 0.1122 |
| 55601 | DDX60 | P15T-E | Human | Esophagus | ESCC | 4.90e-08 | 3.47e-01 | 0.1149 |
| 55601 | DDX60 | P17T-E | Human | Esophagus | ESCC | 1.88e-08 | 4.10e-01 | 0.1278 |
| 55601 | DDX60 | P20T-E | Human | Esophagus | ESCC | 5.53e-12 | 3.44e-01 | 0.1124 |
| 55601 | DDX60 | P21T-E | Human | Esophagus | ESCC | 2.71e-14 | 4.34e-01 | 0.1617 |
| 55601 | DDX60 | P22T-E | Human | Esophagus | ESCC | 1.89e-09 | 1.04e-01 | 0.1236 |
| 55601 | DDX60 | P23T-E | Human | Esophagus | ESCC | 1.13e-04 | 1.95e-01 | 0.108 |
| 55601 | DDX60 | P24T-E | Human | Esophagus | ESCC | 4.51e-21 | 5.26e-01 | 0.1287 |
| 55601 | DDX60 | P26T-E | Human | Esophagus | ESCC | 9.22e-10 | 2.75e-01 | 0.1276 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:0030522110 | Esophagus | ESCC | intracellular receptor signaling pathway | 170/8552 | 265/18723 | 8.58e-10 | 2.09e-08 | 170 |
| GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
| GO:003952813 | Esophagus | ESCC | cytoplasmic pattern recognition receptor signaling pathway in response to virus | 28/8552 | 34/18723 | 1.21e-05 | 1.12e-04 | 28 |
| GO:009858613 | Esophagus | ESCC | cellular response to virus | 56/8552 | 84/18723 | 8.20e-05 | 6.01e-04 | 56 |
| GO:003952913 | Esophagus | ESCC | RIG-I signaling pathway | 22/8552 | 27/18723 | 1.49e-04 | 9.92e-04 | 22 |
| GO:000275313 | Esophagus | ESCC | cytoplasmic pattern recognition receptor signaling pathway | 41/8552 | 60/18723 | 3.25e-04 | 1.91e-03 | 41 |
| GO:00395313 | Esophagus | ESCC | regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 18/8552 | 24/18723 | 3.43e-03 | 1.41e-02 | 18 |
| GO:00395355 | Esophagus | ESCC | regulation of RIG-I signaling pathway | 15/8552 | 20/18723 | 7.60e-03 | 2.71e-02 | 15 |
| GO:003052222 | Liver | HCC | intracellular receptor signaling pathway | 171/7958 | 265/18723 | 3.00e-13 | 1.61e-11 | 171 |
| GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
| GO:0039528 | Liver | HCC | cytoplasmic pattern recognition receptor signaling pathway in response to virus | 30/7958 | 34/18723 | 3.88e-08 | 8.39e-07 | 30 |
| GO:00027533 | Liver | HCC | cytoplasmic pattern recognition receptor signaling pathway | 46/7958 | 60/18723 | 7.37e-08 | 1.49e-06 | 46 |
| GO:00022211 | Liver | HCC | pattern recognition receptor signaling pathway | 107/7958 | 172/18723 | 1.37e-07 | 2.58e-06 | 107 |
| GO:00395291 | Liver | HCC | RIG-I signaling pathway | 24/7958 | 27/18723 | 7.23e-07 | 1.12e-05 | 24 |
| GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:00985861 | Liver | HCC | cellular response to virus | 57/7958 | 84/18723 | 2.30e-06 | 3.11e-05 | 57 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DDX60 | SNV | Missense_Mutation | novel | c.1426G>T | p.Asp476Tyr | p.D476Y | Q8IY21 | protein_coding | deleterious(0.01) | probably_damaging(0.962) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DDX60 | SNV | Missense_Mutation | novel | c.4583N>T | p.Tyr1528Phe | p.Y1528F | Q8IY21 | protein_coding | deleterious(0.01) | possibly_damaging(0.886) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
| DDX60 | SNV | Missense_Mutation | novel | c.2341N>A | p.Ala781Thr | p.A781T | Q8IY21 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| DDX60 | SNV | Missense_Mutation | c.2306N>A | p.Arg769Gln | p.R769Q | Q8IY21 | protein_coding | deleterious(0.04) | possibly_damaging(0.463) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| DDX60 | SNV | Missense_Mutation | c.1613N>C | p.Phe538Ser | p.F538S | Q8IY21 | protein_coding | deleterious(0) | possibly_damaging(0.839) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| DDX60 | SNV | Missense_Mutation | c.1528N>C | p.Asp510His | p.D510H | Q8IY21 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| DDX60 | SNV | Missense_Mutation | c.3790C>T | p.His1264Tyr | p.H1264Y | Q8IY21 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DDX60 | SNV | Missense_Mutation | c.1780N>A | p.Glu594Lys | p.E594K | Q8IY21 | protein_coding | tolerated(0.12) | benign(0.043) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| DDX60 | SNV | Missense_Mutation | c.3231N>C | p.Lys1077Asn | p.K1077N | Q8IY21 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| DDX60 | SNV | Missense_Mutation | novel | c.362N>G | p.Thr121Arg | p.T121R | Q8IY21 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |